Abstract 1841P
Background
Objective evaluation of a patient’s health status is challenging and may frequently lead to unplanned therapy modifications. Therefore, we aimed to evaluate the feasibility of wrist-worn wearable health device (WAD) to predict objectively the likelihood of therapy modifications in patients with metastatic cancer.
Methods
We prospectively enrolled therapy naïve patients with metastatic solid tumors before their first administration of systemic therapy. Patients were asked to wear a WAD (Garmin Vivosmart 4) for 6 months 8 hours per day and charge it at night. Raw sensor data was read out directly from the WADs. Each cycle, therapy was classified either “planned” or “unplanned” (delay, dose reduction, or omission of a substance).
Results
Overall, 437 patients were screened, and 84 (19.2%) patients gave their consent of which 7 (8.3%) dropped out before completing the 6-month study period. For the interim analysis, we included data from the 50 patients who already completed the study (21 female, 29 male, median age 61 (IQR 51.5, 66.75). Overall, 348 therapy cycles (86.5%) were administered “planned” and 54 (13.5%) were ”unplanned”. Patients wore the WAD in median 46 days (IQR (20, 65 days)) or 30% of the anticipated timeframe (IQR 16-62y). Eight (16%) patients wore the WAD at least 90 days, 6 (12%) on 60-90 days, 19 (38%) on 30-60 days and 17 (34%) 30 days or less. In 96% of worn days, the WAD recorded data for at least 6 hours or more. Average step-count per patient per day was 4628 with a median of 3349 steps (IQR 1,602; 5,203)). The number of worn days per cycle was significantly lower in patients with need for a modified next therapy cycle (median 4 days, IQR (1-8)) than in patients that had their therapy administered as planned (median 8 days, IQR (2, 15), p=0.021). The number of steps taken was not significantly different between these two groups (median “unplanned” 1,519; IQR (395; 4,550), median “planned” 2,962; IQR (973; 6,512), p=0.051).
Conclusions
WADs in oncologic outpatient use are a safe way to gather large amounts of data on parameters such as steps and wear time. Overall wear time was low and significantly associated with the need for therapy modifications (delay, dose reduction, omission of a substance) in the next cycle.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Clinical Division of Oncology Department of Medicine I Medical University of Vienna.
Funding
The financial support by the Austrian Federal Ministry for Digital and Economic Affairs, the National Foundation for Research, Technology and Development and the Christian Doppler Research Association is gratefully acknowledged.
Disclosure
A.S. Berghoff: Financial Interests, Personal, Research Funding: Daiichi Sankyo, Roche; Financial Interests, Personal, Advisory Role, and/or honoraria for lectures/consultation: Roche, Bristol Myers Squibb, Daiichi Sankyo, AstraZeneca, CeCaVa; Financial Interests, Personal, Advisory Role, and/or honoraria for lectures/consultationand/or honoraria for lectures/consultation: Merck; Financial Interests, Personal, Other: Roche, Amgen, AbbVie. A.M. Starzer: Financial Interests, Personal, Invited Speaker, Lecture honoraria: AstraZeneca; Financial Interests, Institutional, Research Grant, Industry partner of institutional Christian Doppler Laboratory: Roche; Non-Financial Interests, Member, National Oncology Society: OeGHO; Non-Financial Interests, Member, Oncology society of USA: ASCO; Other, Other, Travel support for conference participation: MSD, Lilly. M. Preusser: Financial Interests, Personal, Advisory Board, and/or honoraria for lectures/consultation: Bayer; Financial Interests, Personal, Advisory Board, consultation: Bristol Myers Squibb, Novartis, Gerson Lehrman Group, CMC Contrast, GSK, Mundipharma, Roche, BMJ Journals, MedMedia, AstraZeneca, AbbVie, Lilly, Medahead, Daiichi Sankyo, Sanofi, Merck, Sharp & Dome, Tocagen, Adastra, Gan & Lee Pharmaceuticals, Janssen, Servier, Miltenyi, Boehringer Ingelheim, Telix, Medscape. All other authors have declared no conflicts of interest.
Resources from the same session
1832P - Physical condition is associated with quality of life in colorectal cancer survivors: Results from a Portuguese and Spanish cohort of patients
Presenter: Luisa Soares Miranda
Session: Poster session 12
1833P - JUMP_START: Optimization of multiprofessional care for young patients with colorectal cancer
Presenter: Kaiyu Xu
Session: Poster session 12
1834P - Accuracy of recommendations by a conversational Artificial Intelligence (AI) cancer mentor application (app): A multi-disciplinary, multi-institutional evaluation report
Presenter: Talia Golan
Session: Poster session 12
1835P - Multi-centre, randomised controlled trial of digital health cancer solution for cancer patients receiving chemotherapy
Presenter: Agnieszka Michael
Session: Poster session 12
1836P - Patient-reported health behaviors (PRHB) among 1850 patients enrolled in a remote patient monitoring (RPM) pathway
Presenter: Maria Alice Franzoi
Session: Poster session 12
1837P - Assessing care complexity in remote patient monitoring (RPM): A cohort study of 2434 cancer patients across 50 sites in France and Belgium
Presenter: Capucine Baldini
Session: Poster session 12
1838P - AI-based smart oncology follow-up system: Prospective application testing and enhancement of clinical efficacy
Presenter: Chunwei Xu
Session: Poster session 12
1839P - Dynamic reporting of treatment related symptoms via ePROs can reversely identify the type of underlying cancer
Presenter: Andreas Trojan
Session: Poster session 12
1840P - Ready for digital health? A national mirror survey exploring the perspectives of both patients and healthcare professionals
Presenter: Florian Scotté
Session: Poster session 12
1842P - The experience of women with breast or gynecological cancer after participation in the online mindfulness-based cancer recovery program (eMBCR)
Presenter: Marie-Estelle Gaignard
Session: Poster session 12